Immunotherapy is a preventive treatment for allergic reaction to substance such as grass pollens, house dust mites, and bee venom.
Subcutaneous immunotherapy (SCIT) and Sublingual immunotherapy (SLIT) are the immunotherapies used for the treatment of allergic rhinitis, allergic asthma, food allergy, venom allergy, and other allergies.
Subcutaneous immunotherapy (SCIT) is the most commonly used and effective form allergy immunotherapy.
Market Dynamics
The global allergy immunotherapy market is expected to witness significant growth over the forecast period, owing to increasing approval of allergy immunotherapy by regulatory authority.
For instance, in 2017, ALk, a pharmaceutical company focusing on prevention, treatment, and diagnosis of allergy, received the U.S. Food and Drug Administration Biologics License Application (BLA) for its house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet Acarizax.
Furthermore, the tablet is also approved in Europe for the indication of house dust mite (HDM) for adults 18 through 65 years of age under the brand name Acarizax.
Key features of the study:
- This report provides an in-depth analysis of the global allergy immunotherapy market, market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global allergy immunotherapy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Stallergenes Greer, ALK-Abello A/S, Allergy Therapeutics, Allergopharma, HAL Allergy Group, Aimmune Therapeutics, DBV Technologies, Leti Pharma, and Jubilant HollisterStier
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global allergy immunotherapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global allergy immunotherapy market
Detailed Segmentation:
- Global Allergy Immunotherapy Market, By Treatment Type:
- Subcutaneous Immunotherapy (SCIT)
- Sublingual Immunotherapy (SLIT)
- Global Allergy Immunotherapy Market, By Allergy Type:
- Allergic Rhinitis
- Allergic Asthma
- Food Allergy
- Venom Allergy
- Others
- Global Allergy Immunotherapy Market, By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Global Allergy Immunotherapy Market, By Region:
- North America
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country/Region
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Stallergenes Greer*
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- ALK-Abello A/S
- Allergy Therapeutics
- Allergopharma
- HAL Allergy Group
- Aimmune Therapeutics
- DBV Technologies
- Leti Pharma
- Jubilant HollisterStier
“*” marked represents similar segmentation in other categories in the respective section.
